University of Thessaly, School of Health Sciences, Department of Biochemistry & Biotechnology, Microbiology-Virology Laboratory, Ploutonos 26 & Aiolou, 41221 Larissa, Greece.
Vaccine. 2010 Dec 10;29(1):26-33. doi: 10.1016/j.vaccine.2010.10.028. Epub 2010 Oct 23.
In this study, the immunity level of the southern Greek population in the 1-10-year, 11-20-year, 21-30-year and 31-40-year age groups with regard to Sabin vaccine strains and a collection of 11 recombinant and three non-recombinant poliovirus vaccine strains was determined. The results showed the lowest neutralization titre in the 21-30-year-age group against poliovirus type 3. Moreover, the capsid coding region of OPV (oral poliovirus vaccine) derivatives was sequenced in order to identify mutations that might lead to antigenic changes. In Sabin-1 derivatives a tendency of accumulation of mutations was observed in or near antigenic sites while in Sabin-2 and Sabin-3 derivatives in sites known to be involved in restoring neurovirulence or eliminating their temperature-sensitive phenotype. It was concluded that the combination of mutations in the capsid coding region and not the number of specific mutations in antigenic sites determines the antigenic properties of OPV derivatives and their reactivity with human sera.
在这项研究中，确定了希腊南部人群在 1-10 岁、11-20 岁、21-30 岁和 31-40 岁年龄组中针对 Sabin 疫苗株和 11 种重组和 3 种非重组脊髓灰质炎疫苗株的免疫水平。结果表明，31-40 岁年龄组对脊髓灰质炎病毒 3 型的中和效价最低。此外，对口服脊髓灰质炎疫苗（OPV）衍生物的衣壳编码区进行了测序，以确定可能导致抗原变化的突变。在 Sabin-1 衍生物中，在抗原位点附近或附近观察到突变的积累趋势，而在 Sabin-2 和 Sabin-3 衍生物中，在已知与恢复神经毒力或消除其温度敏感表型有关的位点。结论是，衣壳编码区中的突变组合而不是抗原位点中的特定突变数量决定了 OPV 衍生物的抗原特性及其与人血清的反应性。
